APRI (Aprinoia Therapeutics) Net Margin %: -61,234.29% (As of Dec. 2023)


What is Aprinoia Therapeutics Net Margin %?

Aprinoia Therapeutics APRI Net Margin % is -61,234.29% as of Dec. 2023.

Net margin is calculated as Net Income divided by its Revenue. Aprinoia Therapeutics's Net Income for the six months ended in Dec. 2023 was $-21.43 Mil. Aprinoia Therapeutics's Revenue for the six months ended in Dec. 2023 was $0.04 Mil. Therefore, Aprinoia Therapeutics's net margin for the quarter that ended in Dec. 2023 was -61,234.29%.

The historical rank and industry rank for Aprinoia Therapeutics's Net Margin % or its related term are showing as below:


APRI's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Aprinoia Therapeutics  (NAS:APRI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Aprinoia Therapeutics Net Margin % Related Terms

Aprinoia Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Net Margin % Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Net Margin %
-4,229.27 -7,165.23 -315.55

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Net Margin % 0.00 -4,635.93 -14,702.02 -79.53 -61,234.29

APRI vs : Net Margin % Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Net Margin % falls into.


Aprinoia Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Aprinoia Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-28.617/9.069
=-315.55 %

Aprinoia Therapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-21.432/0.035
=-61,234.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -61,234.29% mean?
Aprinoia Therapeutics (APRI) has a Net Margin % of -61,234.29% as of Dec. 2023. Net margin is the ratio of total net income to net sales. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Net Margin % too high?
Aprinoia Therapeutics' current Net Margin % is -61,234.29%.
How does Aprinoia Therapeutics' Net Margin % compare to ?
Aprinoia Therapeutics' Net Margin % of -61,234.29% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Net Margin % is -61,234.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Net Margin % of -61,234.29%. The current Net Margin % is -61,234.29%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Net Margin % is -61,234.29% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.